Guidance for physicians on the detection of child sexual exploitation
Monday, 18 May 2015 14:41
Karen Rogstad, Dawn Wilkinson and Sophie Forsyth
Produced for the RCP on behalf of the Young Adults and Adolescents Steering Group of the RCP, the Joint Specialty Committee for Genitourinary Medicine, and the Adolescent Special Interest Group of the British Association for Sexual Health and HIV.
This guidance is intended to support physicians to recognise potential cases of child sexual exploitation (CSE) and seek support to protect vulnerable children and young people.
An awareness of CSE is essential for physicians. Physicians could be working with current victims of CSE, young people at risk of CSE, or children and adults who have previously been victims of CSE. In law, a child is anyone who has not yet reached their 18th birthday. However, some young people aged 18 or over may have vulnerabilities that put them at risk of CSE, or it may be ongoing into young adulthood.
Recent high-profile cases have drawn attention to CSE. In many cases, reviews have shown that these young people had attended many adult services where CSE could have been, but was not, considered. Reports by the Office of the Children’s Commissioner’s Inquiry into Child Sexual Exploitation by Gangs and Groups have shown that CSE is extensive. Doctors cannot ignore this issue.
- View guidance [ 340 kb ]
'Together for Health': Welsh Government Liver Disease Delivery Plan
Thursday, 07 May 2015 08:52
The Welsh Government has published its liver disease delivery plan - Together for Health.
It is split into six themes:
- Preventing liver disease and promoting liver health
- Timely detection of liver disease
- Fast and effective care
- Living with liver disease
- Improving information
- Targeting research
For each theme, the following is set out:
- Key service issues
- Specific priorities
- Population outcome indicators and NHS assurance measures
NCEPOD - call for study proposals 2015
Friday, 01 May 2015 10:05
NCEPOD has announced that the 2015 call for study proposals is now open. Members are invited to submit original study proposals, which will be considered as possible forthcoming studies. Study proposals should be relevant to the current clinical environment and, very importantly, should have the potential to contribute original work to the subject.
Those BSG members wishing to submit a study proposal should contact the relevant BSG Section chair to discuss a formal submission. Proposals must be submitted by 25th September 2015.
BSG supported STOPAH study shows a lack of evidence for drug treatments
Wednesday, 29 April 2015 08:22
The survival of patients with alcohol-related hepatitis is not being significantly improved by the main drugs currently widely used in treatment of this condition, according to a major new National Institute for Health Research sponsored study supported by members of the British Society of Gastroenterology.
Senior health professionals are highlighting an 'urgent need' for investment into research for the prevention and treatment of alcohol-related liver disease. Documented in the New England Journal of Medicine¸ a trial of over 1,000 patients using prednisolone and pentoxifylline did not achieve a statistically significant reduction in mortality after 28 days, 90 days, or a year.
The alarming findings come at a time when the incidence of alcohol-related liver disease is rapidly increasing, however the report does also show that the overall mortality has fallen compared to studies done in the past which suggests that specialist in hospital care of these very sick people can improve outcomes, and what could be achieved more widely contrasting with the 2013 NCEPOD report on the care of cirrhosis where care was often found to be lacking.
Commenting, British Society of Gastroenterology Vice President (Hepatology), Dr Stephen Ryder, said:
"STOPAH has answered some key questions in the treatment of alcohol-related hepatitis and highlighted the urgent need for research into the prevention and treatment of alcohol-related liver disease, which is on the rise.
Whilst the study does suggest that patients are receiving better care than reported in previous reviews, unfortunately it also shows that neither steroids or pentoxifylline are effective treatments and there is no real indication now for their use.
The stark finding in STOPAH remains the high late mortality related to resumption of alcohol intake and emphasises the need for universal implementation of the BSG recommendations on alcohol care teams, that seems likely to be a far more effective intervention than any medical therapy for the acute episode.
One of the great successes of this study was to show that UK hepatologists and gastroenterologists from over 50 UK centres can collaborate to deliver important large scale clinical studies aimed at improving outcomes for patients with liver disease."
Page 1 of 4